Company Overview
Snapshot
Founded in January 2007, VVT Medical operates with 11–50 employees and has raised a total of $2.6 million across two funding rounds from I3 Capital Group. The company went public on the TSX Venture Exchange in July 2025.
Business overview
VVT Medical specializes in the research, development, manufacturing, and commercialization of minimally invasive, non-thermal, non-tumescent solutions for treating varicose veins. Its core product, the ScleroSafe platform, combines best practices in vein treatment with a patented delivery system, enabling physicians to perform quick, office-based procedures without the need for tumescent anesthesia or costly capital equipment. The company's solutions, including ScleroSafe with V-Block, are designed to treat severely dilated and challenging Great Saphenous Vein conditions, serving the healthcare and life sciences sectors, particularly healthcare providers.
Strategic signal
VVT Medical is actively expanding its global commercial footprint and product adoption. In June 2026, the company secured an exclusive distribution agreement in Greece and also expanded into the Dominican Republic by appointing Antilles Medical as its exclusive distributor. This indicates a strong strategic focus on international market penetration and growing product accessibility, signaling potential for increased revenue streams and market share to investors.
Log in to access full profile ›Company Intelligence Q&A
- What is VVT Medical's primary focus?
- VVT Medical specializes in developing, manufacturing, and commercializing minimally invasive, non-thermal, non-tumescent solutions for the treatment of varicose veins.
- When did VVT Medical go public?
- VVT Medical Inc. announced the commencement of trading on the TSX Venture Exchange in July 2025.
- Has VVT Medical expanded its European commercial footprint recently?
- Yes, in June 2026, VVT Med expanded its European commercial footprint through an exclusive distribution agreement in Greece. Additionally, in April 2026, VVT Med signed its largest European distribution agreement to date, with the distributor also joining as an investor.
- What is the ScleroSafe system?
- The ScleroSafe system is VVT Medical's flagship platform that enables physicians to perform quick, office-based procedures for varicose vein treatment without the need for tumescent anesthesia or costly capital equipment. In May 2026, VVT Med announced the first patients were treated with the ScleroSafe system in Italy.
- Did VVT Medical secure a distribution deal in India?
- Yes, in November 2025, VVT Med signed a $3.7 million distribution agreement in India.